AstraZeneca still eyes US vaccine filing despite another delay

AstraZeneca confirmed on Thursday plans to seek a standard approval of its coronavirus vaccine Vaxzevria in the U.S., and not an emergency use authorization — a speedier path to market — as originally intended.